Head-to-head · WeighScore
Mint Med vs Trillium Meds
By GLP-1 ScorecardUpdated
Score comparison
Mint Med has the higher recorded score — 78.7/100 to 69.4/100.
Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Mint Med | Trillium Meds |
|---|---|---|
| WeighScore | 78.7/100 | 69.4/100 |
| Grade | C+ | C |
| Site position | #45 | #140 |
| Semaglutide | $117/mo | $119/mo (3-month plan, compounded) |
| Tirzepatide | $159/mo | $199/mo (3-month plan, compounded) |
| Coverage | 36 states | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #45 · C+
FDAWarning letter issued to Glow Medispa, LLC dba Mint Med in June 2026. See the FDA warning-letter database.
Strengths
- $117 sema / $159 tirz
- LegitScript-verified
- Both molecules
What to consider
- Only 36 states
- Injection-only
- Monitoring detail sparse
Site position #140 · C
Strengths
- LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
- All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
- Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
- Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
- Klarna and Affirm financing available; pause anytime with no long-term commitment required
What to consider
- No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
- Small single-operator platform may limit capacity and support consistency as patient volume grows
- Compounded medications are not FDA-approved; newer platform with limited long-term public track record
- Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
- No live video consult disclosed; async intake-form-based provider review by external licensed provider network
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.